“It’s a scalable model that can be engineered to carry the genetic variants that give rise to all these diseases … and it gives us incredible access to things we never have done before,” lead researcher Anand told The Washington Post. “We can screen drugs, we can ask questions, we can follow the development at every stage.”
Because the researchers are patenting their process, they have not released data describing their methods. (They have also formed a commercial startup.) But according to an OSU press release, the team has already used the technique to model autism, Alzheimer’s, and Parkinson’s disease “in-a-dish,” and hopes to receive funding from the Small Business Technology Transfer program to use the model in drug development.
The announcement comes on the heels of another advance in organotypic brain modeling – a 3D bioprinted structure developed by Rodrigo Lozano and colleagues at the University of Wollongong in Australia. A functional brain “organoid” that can be subjected to environmental manipulations, or genetically engineered to reproduce inherited conditions, holds great promise for human-relevant toxicity testing, more efficient drug-candidate screening, and the study of neurodevelopmental and neurodegenerative diseases.